A 56-year-old woman with a background of neuromyelitis optica spectrum disorder associated with aquaporin-4 antibodies (AQ4-NMOSD) treated with azathioprine, presented with a 2-month history of declining mobility, weight loss and hoarse voice. She had a history of autoimmune thyrotoxicosis and treated hypertension. Given her smoking history, the initial clinical concern was of malignancy. Neurophysiological examination identified severely attenuated responses from the upper and lower limb motor units, with significant neurophysiological incrementation postexercise, indicating a presynaptic neuromuscular junction disorder. Antibody testing showed markedly raised antibodies to the p/q subtype voltage-gated calcium channels, and she was diagnosed with Lambert-Eaton myasthenic syndrome (LEMS). She was treated with 3,4-diaminopyridine and rituximab to maintain remission. Follow-up serial fluorodeoxyglucose positron emission tomography (FDG-PET) CT scans have yet to identify an underlying malignancy. LEMS is associated with additional autoimmune diseases in about half of cases. This case illustrates the importance of recognising other treatable autoimmune conditions in the context of NMOSD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/pn-2024-004446 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea.
J Clin Neurol
March 2025
Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
Background And Purpose: Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation.
View Article and Find Full Text PDF[Shared Decision-Making in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder].
Brain Nerve
March 2025
Department of Neurology, Gifu University Graduate School of Medicine.
In multiple sclerosis and neuromyelitis optica spectrum disorders, several new, highly effective drugs have been developed in recent years, and the prognosis for patients has improved. However, treatment has become more complex, and healthcare professionals should explain the efficacy and safety of drugs to patients and engage in shared decision-making (SDM) that considers the patient's preferences and values. Further studies are required to determine whether SDM is associated with patient outcomes.
View Article and Find Full Text PDFIntravitreal delivery of NMO-IgG causes primary retinal damage in the absence of optic nerve injury.
J Neuroinflammation
March 2025
College of Health and Life Science, University of Health and Rehabilitation Sciences, Qingdao, Shandong, People's Republic of China.
Background: Neuromyelitis Optica (NMO) is a neuroimmune disorder primarily driven by autoantibodies against aquaporin 4 (AQP4), known as NMO-IgG. Although the mechanisms underlying NMO-IgG-induced retinopathy are not fully understood, the high expression of AQP4 in retinal Müller cells suggests a direct interaction that may trigger inflammatory processes in the retina. Previous studies indicate that microglia play a critical role in mediating immune responses, leading to neuronal dysfunction.
View Article and Find Full Text PDFMarkedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?
Mult Scler Relat Disord
March 2025
Department of Neurology, Mayo Clinic, Rochester, MN, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA. Electronic address:
Background: The diagnosis of multiple sclerosis (MS) is based on the revised McDonald's criteria, which includes clinical history, neurological examination, MRI findings and cerebrospinal fluid (CSF) analysis necessitating the exclusion of alternative explainable diagnoses. Markedly elevated CSF white blood cells (WBCs) over 50 (units) is considered a "red flag" for an alternative diagnosis apart from MS.
Objective: To present a man with typical relapsing-remitting MS (RRMS) despite markedly elevated CSF WBCs.
Evaluation of Brain and Spinal Cord Lesions and Cerebrospinal Fluid Analysis in Detecting Demyelinating Diseases in Patients with Optic Neuritis.
Neuroophthalmology
November 2024
Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Optic neuritis can be an early sign of demyelinating diseases like multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody-associated diseases (MOGAD). We investigated the presence or absence of head and spinal cord lesions on magnetic resonance imaging (MRI) and assessed whether cerebrospinal fluid (CSF) tests are useful in detecting demyelinating disease in patients with first diagnosed optic neuritis. We conducted a retrospective study of 111 patients (47 idiopathic, 19 NMOSD, 16 MOGAD, 16 MS, 6 optic neuritis with cerebral lesions but that does not meet the McDonald's criteria for MS (ON+)), and 7 chronic relapsing inflammatory optic neuropathy) diagnosed with optic neuritis without cerebral or spinal symptoms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!